Timothy Walsh is currently Professor of Medical Microbiology and Antibiotic Resistance at Cardiff University, Cardiff, Wales, and leads an active research in antibiotic resistance. Previously, he was a Reader in Medical Microbiology at the University of Bristol following several postdoctoral research positions in London, UK. After obtaining a BSc in Applied Laboratory Science and a Post Graduate Diploma of Immunology/Microbiology at the University of Tasmania in Australia, Prof. Walsh earned his PhD in Molecular Microbiology at the University of Bristol. He is in the process of obtaining his MRCPath (London) and DSc (Australia). Prof. Walsh is a member of the Australian Society of Microbiology, Society for General Microbiology (UK), British Society of Antimicrobial Chemotherapy, American Society of Microbiology and European Society of Clinical Microbiology and Infectious Diseases. Prof. Walsh’s research is focused on unusual mechanisms of antimicrobial resistance and how they are mobilized into the clinical sector and spread once established. He has published and presented over 400 papers, in particular on the characterization of β-lactamases within Gram-negative bacteria. His interests include designing and evaluating new antimicrobials as well as blending molecular and clinical epidemiology in large scale studies in developing countries. His research has been funded by the Wellcome Trust, European Union, British Society of Antimicrobial Chemotherapy, BBSRC, Merck etc. He is advisory on many EC steering groups and the WHO, and is a consultant to the Chinese CDC.